



June 09, 2022

To,

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400 001

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip code: 512529

Symbol: SEQUENT

Subject: Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended March 31, 2022.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**

Krunal Shah
Company Secretary & Compliance Officer



Encl.: As above

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, India

Tel: +91-22-4111-4777 | CIN: L99999MH1985PLC036685

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

Disclosure of related party transactions on consolidated basis

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

A List of related parties

List of related parties with whom transactions have taken place during the six month ended 31 March 2022

a) Key management personnel (KMP)

Mr. Manish Gupta, Chief Executive Officer & Managing Director (Till 10 April 2022)

Mr. Sharat Narasapur, Joint Managing Director

Mr. Tushar Mistry, Chief Financial Officer (Till 31 May 2022)

Mr. Krunal, Shah, Company Secretary

Dr. Kamal K Sharma, Independent Director

Mr. Milind Sarwate, Independent Director

Mr. Gregory Andrews John, Non-Executive Director

Dr. Fabian Kausche, Non-Executive Director

Dr. Kausalya Santhanam, Independent Director

b) Transactions with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries (refer note as below)

Strides Pharma Sciences Limited (formerly known as Strides Shasun Limited)

Strides Emerging Markets Limited

Tenshi Kaizen Private Limited

Stelis Biopharma Private Limited

Solara Active Pharma Sciences Limited

Sequent Penems Private Limited

Note: Subsequent to change of control in the SeQuent Scientific Limited, the above entities have ceased to be related parties w.e.f. 17 August 2020 under the Companies Act, 2013. The Company had filed requisite application with the Stock Exchanges as prescribed under SEBI LODR regulations seeking re-classification of the erstwhile 'Promoter Group' into 'Public Category' and the Stock Exchange approval for the same was received on 01 November 2021.



SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7,Road No. 22, Wagle Industrial Area, Thane (W), Mumbai – 400604, India

Tel: +91 22 41114777 | FAX: +91-22-41114754 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

B Transactions during the period 01 October 2021 to 31 March 2022

Particulars	₹ in Million
i) Transactions with KMP	
Managerial remuneration (*)	
Mr. Manish Gupta	
Short Term Benefits	11.81
Share based payments	52.78
Mr. Sharat Narsapur	
Short Term Benefits	6.69
Share based payments	3.69
Mr. Tushar Mistry	
Short Term Benefits	3.28
Share based payments	2.58
Mr. Krunal Shah	
Short Term Benefits	0.92
Directors sitting fees	
Dr. Kamal K Sharma	1.60
Mr. Milind Sarwate	1.20
Mr. Gregory Andrews John	0.40
Dr. Fabian Kausche	0.40
Dr. Kausalya Santhanam	0.50
Directors Commission	
Dr. Kamal K Sharma	0.39
Mr. Milind Sarwate	0.39
Mr. Gregory Andrews John	0.78
Dr. Fabian Kausche	0.78
Dr. Kausalya Santhanam	0.39
ii) Transaction with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries	
Sale of materials / services	
Strides Pharma Sciences Limited	-
Strides Emerging Markets Limited	0.01
Solara Active Pharma Sciences Limited	5.00
Stelis Biopharma Private Limited	-
Tenshi Kaizen Private Limited	-
Purchase of materials	
Solara Active Pharma Sciences Limited	19.08
Payment towards lease obligation and finance costs	
Solara Active Pharma Sciences Limited	0.74

(*) Expenses towards gratuity and compensated absences provisions are determined actuarially on an overall Group basis at the end of each year and accordingly have not been considered in the above information.

Place: Thane
Date: 09 June 2022



Krunal Shah
Krunal Shah
Company Secretary

Sequent Scientific Limited